Histone acetylation is a prominent epigenetic modification of the central nervous system that is unequivocally associated with an increase in the rate of gene transcription. Because gene transcription, in turn, plays an important role in long-lasting forms of memory, histone acetylation generally favors long-term memory, whereas histone deacetylation impinges on it. Histone acetylation is also amenable to pharmacological interventionspredominantly by the use of histone deacetylase (HDAC) inhibitors-and has therefore spurred considerable interest as a putative target of cognitive enhancement. Because of the ubiquitous presence of histone acetylation, HDAC inhibitors have great potential not only to treat cognitive impairment resulting from neurodevelopmental and neurodegenerative disorders but also to serve as cognitive enhancers for the cognitively healthy. In this review, we summarize the state of the art of HDAC inhibitors as cognitive treatments or cognitive enhancers; describe a new model of their mode of action, epigenetic priming; and caution against their unsupervised usage, despite their overall great promise. 
INTRODUCTION
Live as if you were to die tomorrow.
Learn as if you were to live forever.
-Mahatma Gandhi If a memory is to last for days, months, or even years, it requires gene expression changes (1) that are coordinated in part by epigenetic modifications (2) (3) (4) . This notion, widely accepted in the neuroscientific community today (2), originated with Francis Crick's 1984 hypothesis that "memory might be coded in alterations to particular stretches of chromosomal DNA" (5, p. 101). Subsequent reports indicated that such codes could be composed of epigenetic modifications that involve histone acetylation (6) , histone phosphorylation (7), DNA methylation (8) , and histone methylation (9) . Epigenetic modification or epigenetics refers to "the structural adaptation of chromosomal regions so as to register, signal, or perpetuate altered activity states" (10, p. 398). The best-understood and most-studied epigenetic modification in the nervous system is histone (H) acetylation, which is the addition of a negatively charged acetyl group to lysine (K) residues on N-terminal histone tails. Histone acetylation diminishes the electrostatic affinity between histone proteins and the negatively charged DNA, thereby promoting a chromatin structure that is more permissive to gene transcription (11) . Histone acetylation is of interest because it may play a role in reinstating memory-promoting transcriptional changes to treat cognitive decline or in boosting memory performance overall. In this review, we discuss the role of histone acetylation in cognitive processes and its potential as a pharmacological target to enhance cognition in health and disease.
THE ROLE OF HISTONE ACETYLATION IN COGNITION
Histone acetylation is enzymatically controlled by histone acetyltransferases (HATs) and histone deacetylases (HDACs). The addition of acetyl groups is catalyzed by HATs, which are grouped according to structural similarities, substrate specificity, and responsiveness to coactivators (12) ; HATs are not covered further in this review. The removal of acetyl groups is catalyzed by HDACs, which, in mammals, are divided into two categories (the zinc-dependent HDACs and the NAD + -dependent HDACs) and four subfamilies (classes I, II, III, and IV). Classes I, IIa, IIb, and IV fall under the first category ( Table 1) ; class III falls under the second. Class III HDACs, which are structurally unrelated to the others, consist of seven NAD + -dependent HDACs named sirtuins, which share sequence homology with the yeast Sir2 protein (13, 14) . For the purpose of this review, we hereafter use the term HDACs to mean only class I, II, and IV HDACs ( Table 1) . The reader is invited to consult the Related Resources at the end of this review for further information about the class III HDACs. In the only study published so far, the HDAC6-selective inhibitor WT-161 had no effect in improving contextual fear memories. The role of HDAC6 in other cognitive processes has not been explicitly tested.
Abbreviations: CNV, copy number variation; LTF, long-term facilitation; TBD, to be determined. Unless otherwise noted, cognitive processes were assessed in mice.
In addition to the conserved HDAC domain, class IIa HDACs have N-terminal extensions with binding sites for HDAC3, MEF2, and other complexes, including histone methyltransferases (13, 14, 17) . All class IIa HDACs have relatively low deacetylase activity and most likely act in concert with other HDACs such as those of class I (18) .
Class IIb HDACs consist of HDAC6 and HDAC10. HDAC6 is the main cytoplasmic deacetylase in mammalian cells, targeting α-tubulin, among other cytoplasmic proteins (19) ; little is known about the function of HDAC10. HDAC6 and HDAC10 contain zinc-finger and leucine-zipper C-terminal expansions to the HDAC catalytic domain, respectively (13) .
HDAC11 is the only member of the class IV HDACs. Its expression is primarily nuclear, and it is structurally similar to the class I HDACs (13) . Little is known about its function.
In the brain, all class I, II, and IV HDAC isoforms are expressed and found primarily in neurons (20) . HDAC2-5 and HDAC11 are also expressed in oligodendrocytes, whereas the expression of all HDACs in astrocytes is low. In brain regions implicated in learning and memory-such as the amygdala, hippocampal formation, and cortical areas-class I HDACs are expressed more highly than are class IIa HDACs (of which HDAC4 shows the highest expression). Furthermore, class IIa HDACs are expressed more highly in the aforementioned brain regions than are class IIb HDACs. HDAC11 is also abundantly expressed in these brain areas. Of the class I HDACs, HDAC2 and HDAC3 are usually more highly expressed than are HDAC1 and HDAC8 (20) . Given this differential abundance and distribution, class I HDACs are the best-studied HDACs with respect to learning and memory (see below).
Increased Histone Acetylation Accompanies Memory Formation
The first indication that histone acetylation might be associated with memory formation was found when Levenson et al. (6) examined H3 and H4 acetylation 1 h and 24 h following contextual fear
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Rubinstein-Taybi syndrome AD: Alzheimer's disease conditioning and latent inhibition, two paradigms of associative learning. H3 acetylation (on K14) was significantly increased in hippocampal area CA1 1 h (but not 24 h) after contextual fear conditioning, whereas no change was observed in overall H4 acetylation. Conversely, H4 acetylation was increased following latent inhibition but not following contextual fear conditioning. The results of this study conceptualized two important aspects of the connection between histone acetylation and memory formation. First, histone acetylation-and with it, structural changes of the chromatin-accompanies memory formation. Second, different learning paradigms are likely to elicit distinct epigenetic signatures in the brain.
Numerous follow-up studies confirmed these findings in contextual fear conditioning (7, 21, 22) , in other brain areas such as the prefrontal cortex (23) and the amygdala (24, 25) , in other memory tasks such as eye-blink conditioning and object recognition (26) , in other phases of a memory's life such as consolidation and reconsolidation/extinction (23-25, 27, 28) , and in organisms other than rodents, e.g., crabs (29) . Although Western blot analysis or immunohistochemistry could detect such acetylation changes on a global scale, more refined studies using chromatin immunoprecipitation (ChIP) clarified that these changes do not occur indistinguishably throughout the chromatin but instead occur gene-specifically. That is, the acetylation changes associate with the promoter regions of learning and memory genes (e.g., zif268 and CREB), which, when hyperacetylated, show a concomitant increase in transcription (22, 23, 30, 31) . Thus, histone acetylation increments favor gene expression programs that are necessary for memory formation.
Decreased Histone Acetylation Accompanies Memory Impairments
Memory impairments are associated with several neurodevelopmental, neuropsychiatric, and neurodegenerative diseases such as Rubinstein-Taybi syndrome (RTS), Rett syndrome, Fragile X syndrome, schizophrenia, depression, addiction, Alzheimer's disease (AD), Huntington's disease, Parkinson's disease, Friedreich's ataxia, and amyotrophic lateral sclerosis. Stunningly, the majority of such disease-related memory impairments seem to be accompanied by decreased histone acetylation (2, 32) , and even memory impairments associated with aging fall into this category (33) . For the purpose of this review, we describe RTS and AD as examples of neurodevelopmental and neurodegenerative diseases, respectively, because these two disorders have the best-understood relationship between cognitive impairment and histone hypoacetylation. We refer the reader to recent reviews that cover the other aforementioned diseases (2, 34, 35) and to Related Resources for further information on this topic as it relates to stress-related disorders. RTS is a rare autosomal-dominant neurodevelopmental disorder (with a prevalence in the United States of 1 in 125,000) that is characterized by developmental and cognitive retardation (36) . RTS is caused by mutations in the transcriptional coactivators p300 and CBP (37, 38) , which possess intrinsic HAT function. Over the past decade, several mouse models have been created in which p300 or CBP was partially or fully deleted (39) (40) (41) (42) (43) . All these mice display cognitive deficits at different intervals following contextual and cued fear conditioning, as well as object recognition tasks, suggesting that p300/CBP-mediated histone acetylation is essential for memory formation. The lack of H2B acetylation in hippocampal area CA1 in haploinsufficient CBP +/− mice further corroborated this notion (39) . A recent study also found decreased histone acetylation on H2A and H2B in RTS-patient-derived lymphoblastoid cell lines (44) , translating the rodent findings to the human disease.
AD is the most common form of senile dementia, and the most common neurodegenerative disease, with an estimated prevalence of 1 in 8 in the world's older population. AD is characterized by a progressive deterioration of cognitive functions and delineated pathophysiologically by amyloid plaque accumulation, neurofibrillary tangles, and neuronal loss in various areas of the brain. More than 95% of all AD cases are termed sporadic, meaning that they have no monogenetic predisposition. Fewer than 5% of all AD cases are hereditary, and they involve mutations in the amyloid precursor protein (APP) and in presenilin 1 and 2 (PS1 and PS2); PS1 and PS2 are implicated in the processing of APP, which ultimately leads to amyloid plaques (45) (46) (47) .
Several studies suggest that AD might be characterized by an overall hypoacetylation of histones, although this evidence is not unequivocal (2) . APP overexpression in mouse neuronal cultures led to decreased H3 and H4 acetylation as well as decreased CBP levels (48) . Moreover, loss of PS1 in conditional knockout mice also reduced CBP levels and the expression of CBP target genes (49) , and H3 and H4 acetylation was reduced in two APP/PS1 mouse models of familial AD (50, 51) . Recently, we found that HDAC2, but not HDAC1 or HDAC3, was upregulated in another two mouse models of AD, the CK-p25 and 5XFAD mice (52) (53) (54) (55) . In the hippocampi of CK-p25 mice, this upregulation of HDAC2 led to its increased binding to the promoter regions of learning and memory genes, which showed a concomitant decrease in histone acetylation and reduced transcription. Importantly, decreasing HDAC2 levels by virus-mediated overexpression of an shRNA against HDAC2 in the CK-p25 hippocampus restored histone acetylation levels, gene expression programs, and memory capacities. This result indicates a causal role of HDAC2-mediated histone acetylation in AD-related memory decline (56). Intriguingly, we also found increased levels of HDAC2 in the hippocampus and entorhinal cortex of postmortem brain samples of AD patients, suggesting that similar mechanisms might be involved in human AD (56). Of note, HDAC2 levels were also increased in cortical areas of patients with another neurodegenerative disease, amyotrophic lateral sclerosis (57), suggesting that elevated HDAC2 levels might be a commonality among different neurodegenerative diseases.
Taken together, RTS-and AD-related cognitive impairments are two examples that demonstrate a causal loss-of-function implication of HATs and a causal gain-of-function implication of HDACs in memory decline. In sum, either process results in a net reduction of histone acetylation, the reversal of which has become a major target of pharmacological interventions.
SMALL-MOLECULE INHIBITORS OF HDACs TO IMPROVE COGNITION
Generally speaking, either activating HATs or inhibiting HDACs can defend against histone hypoacetylation. Historically, the latter has proven to be more readily achievable than the former, dating back to as early as 1977 (58). Moreover, because aberrant gene expression is a hallmark of various types of cancer, this proof-of-principle study spurred immense interest in the epigenetic machinery behind such transcriptional changes (59) years before epigenetic mechanisms were discovered to be implicated in cognitive processes. Since then, many more refined and potent HDAC inhibitors (HDACis) have been successfully applied in different types of cancer (60), and several of these HDACis have also shown promising effects in restoring brain histone acetylation levels in cognitive disorders (61).
Which HDAC(s) to Target?
As with all pharmacological interventions, the question of target specificity is important. Of the class I HDACs, HDAC2 and HDAC3 regulate learning and memory ( Table 1) . When both HDAC1 and HDAC2 were overexpressed and deleted in a groundbreaking study that involved the generation of four novel mouse lines, HDAC2, but not HDAC1, could be identified to regulate associative and spatial memory (62). HDAC2-overexpressing mice had impaired memory performance, whereas HDAC2-knockout mice had enhanced memory performance. Such
COGNITIVE EXTINCTION
Whereas memory improvement is desired in some cases, memory extinction is desired in others. For example, if extinction of traumatic memories is the goal, then cognitive weakening rather than cognitive enhancement is pursued. HDAC inhibitors (HDACis) have proven useful for memory extinction because of their role in the labile period induced by the recall of a memory, during which the memory being recalled can be either strengthened or weakened in a process termed reconsolidation (112) (113) (114) . If the conditioned stimulus of an associative memory is newly and repeatedly presented in a safe environment, a new association will be learned; this association can be facilitated by HDACis such as sodium butyrate (NaB), valproate, or trichostatin A (TSA) (23, 27) . In the prefrontal cortex, such extinction learning was accompanied by increased H4 acetylation at the Bdnf P4 promoter (23) , suggesting an implication of increased cortical histone acetylation in extinction learning. As a recent study revealed, HDAC1 shRNA-mediated knockdown and intrahippocampal injections of MS-275 impaired extinction training, suggesting that inhibition of HDAC1 does not play a role in extinction learning (64). More research is needed to assess the potential of different HDACis as treatments for anxiety disorders.
cognitive enhancement coincided with increased histone acetylation overall, especially at the promoter regions of a variety of learning and memory genes in the hippocampus, where this enhanced plasticity was also accompanied by increased dendritic arborization and synaptic density. Similar results were obtained when HDAC3 was focally deleted in the mouse hippocampus through the use of the Cre-Lox system: Hippocampal histone acetylation increased, as did the expression of the immediate early gene c-fos, and the animals' memory performance on a specific object-location task improved (63). However, when a more classical memory paradigm of object recognition was used, no cognitive enhancement in the HDAC3 flox/flox mice was observed. This finding also applies to fear memories, which were unaffected in HDAC3 flox/flox mice (M.A. Wood, personal communication). This discrepancy could indicate a general role for HDAC2 and a more refined role for HDAC3 in cognitive control.
For the other class I HDACs, HDAC1 and HDAC8, no direct role immediately related to learning and memory has been identified. However, HDAC1 has recently been implicated in memory extinction (64) (see sidebar, Cognitive Extinction).
No causative involvement in mammalian cognition has been found for the other classes of HDACs (65). Nonetheless, several studies in other model organisms have indicated that the class IIa HDACs HDAC4 and HDAC5 might play a role in learning and memory. In a thermotaxic memory task in Caenorhabditis elegans, the deletion of hda4, a homolog of the mammalian HDAC4, led to enhanced long-term memory (66) . Conversely, overexpression of HDAC4 impaired longterm memory. Interestingly, refining the deletion of HDAC4 to its cytoplasmic fraction also improved memory, suggesting a more important cytoplasmic function of HDAC4 with respect to cognitive capacities. As for HDAC5, in Aplysia, sensory neurons receiving inputs from the inhibitory transmitter FMRFamide did not display long-term-memory-related synaptic plasticity in forms of long-term facilitation in part because HDAC5 was recruited to the neurons and induced histone hypoacetylation (67) . Similar findings in mice confirm such a memory-impairing role for HDAC5. In a pharmacological mouse model of schizophrenia with object-recognition memory deficits, HDAC5 was upregulated in the prefrontal cortex while H3 acetylation was reduced (68) . Furthermore, a recent study investigating copy number variation between schizophrenic patients (with cognitive disabilities) and healthy control subjects showed that HDAC9 was among the top hits (69) . Lastly, the class IIb HDAC6 can probably be ruled out as a member of the memory-enhancing HDAC family because chronic treatment of wild-type mice with the HDAC6-specific HDACi WT-161 had no effect (62). Therefore, the class I HDACs HDAC2 and HDAC3 represent confirmed targets for cognitive enhancement strategies; HDAC1, HDAC4, HDAC5, and HDAC9 are more speculative targets that are nevertheless worth investigating further.
Classes of HDAC Inhibitors
Small molecules that inhibit the functions of HDACs, i.e., HDACis, are divided into four major classes based on their structure ( Table 2 ). The first class consists of the carboxylic acids sodium butyrate (NaB), phenylbutyrate, and valproic acid (valproate), which display selective inhibition of class I HDACs with negligible effects on other HDACs (61). The second class consists of the hydroxamic acids trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), the SAHA derivatives pyroxamide and oxamflatin, and compounds derived from the marine sponge Psammaplysilla purpurea such as NVP-LAQ824 and NVP-LBH589 (70) . Hydroxamic acids inhibit class I and II HDACs with roughly equal potency (61, 70). The third class of HDACis, which contains a benzamide group in its chemical structure, includes members MS-275 and RGFP136, which inhibit class I HDACs with increased selectivity toward HDAC1 and HDAC3, respectively (61). Lastly, the fourth class of HDACis consists of cyclic tetrapeptides, most of which are natural products. Members of this group of HDACis include the fungus-derived trapoxin, chlamydocin and HC toxin, the bacterial FK228, and their derivatives (70) . In vitro, this HDACi class displays selectivity toward class I HDACs. Crystallographic studies with TSA and SAHA (71) have shown that these HDACis inhibit the deacetylase activity of HDACs by direct interaction with the catalytic domain of the enzyme, where they chelate the active site's zinc ion, which is necessary for the deacetylase function.
In the context of learning and memory, only the first three classes of HDACis have been explored ( Table 2) . No standard procedure has been applied with respect to the type of HDACi used, the route of administration [intraperitoneally (i.p.), orally, or via direct brain injection], the dose of the compound administered, the time frame of the compound administration (chronic versus acute), the species used (rodents versus nonrodents; mouse versus rat), or the age and sex of the animal tested. Therefore, comparing these studies head to head is impossible. Moreover, only a few studies have measured the absorption, distribution, metabolism, excretion and pharmacokinetic parameters of these compounds, and clear biomarkers in the brain for their efficient blood-brain-barrier crossing and mode of action are still lacking. Despite these limitations, which are currently being addressed both in academia and in the pharmaceutical industry, several of these HDACis have shown promising effects in either restoring cognitive functions in cognitively disabled animals or enhancing memory performance in healthy ones.
HDAC Inhibitors as Treatments Against Cognitive Dysfunctions
In this review, we cover RTS and AD as the best-described cases of cognitive dysfunctions that are amenable to HDACi treatment. For a full list of other central nervous system diseases characterized by cognitive dysfunctions and potentially amenable to HDACi treatments, the reader is referred to other recent reviews (2, 14, 32, 65 ).
HDACis have been tested in three mouse models of RTS: (a) the haploinsufficient CBP CA1 but also restored cognitive functions as assessed by contextual fear conditioning. A similar trend was observed for cued fear conditioning, although this effect was not significant (39) . Likewise, i.p. injections of TSA (2 mg kg −1 ) before behavioral testing restored object-memory deficits in the CBP {HAT} mice; this restoration was accompanied by increased H3 acetylation (40) . Furthermore, posttraining injections of NaB (1.2 g kg −1 , i.p.) improved object-recognition memory in CBP KIX/KIX mice (72) . These results suggest HDACis as a potential therapeutic option for the cognitive decline seen in RTS. Intriguingly, TSA (2 μM) also restored histone acetylation levels to control conditions in RTS-patient-derived lymphoblastoid cell lines (44) , providing an in vitro proof of principle of the applicability of HDACis for human patients.
HDACi treatment might also constitute a new avenue for treating cognitive dysfunctions associated with AD and AD-related neurodegeneration. The first study to report such an effect investigated the administration of NaB in the CK-p25 mouse model of AD-related neurodegeneration and memory decline (73) . Daily NaB administration (1.2 mg kg −1 , i.p.) over four weeks reversed neurodegeneration-associated memory impairments in associative and spatial memory tasks, both before and after memories had time to consolidate. Remarkably, such rescue of cognitive functions occurred despite profound neuronal loss, suggesting that long-term memories are not lost but instead merely compromised. This notion is further corroborated by increased synaptic density upon NaB treatment, suggesting restored plasticity in the surviving neurons (73) . Recently, we tied this reduced cognitive functioning to an epigenetic blockade mediated by HDAC2 (56), and because the class I-selective HDACi NaB is known to efficiently inhibit HDAC2 activity (61), the NaB-mediated rescue likely acted through HDAC2 inhibition.
Similar results were obtained when APP/PS1 mouse models of familial AD were either chronically or acutely treated with HDACis. Following two to three weeks of i.p. treatment with NaB (1.2 g kg −1 ), valproic acid (100 mg kg −1 ), or SAHA (50 mg kg −1 ), contextual fear memory was indistinguishable from that of wild-type control animals (74) . In addition, when TSA (2 mg kg −1 , i.p.) was injected into the APP/PS1 mice acutely before contextual fear conditioning, fear memory impairment was also abolished (50) . In this latter case, the memory improvement was accompanied by restored hippocampal acetylation. Similar results were obtained when another APP/PS1 mouse model was treated chronically with NaB (1.2 g kg −1 , i.p.); the treatment rescued the animals' contextual and cued fear memory deficits and increased hippocampal histone acetylation (51) .
Similarly, chronic administration of phenylbutyrate (200 mg kg −1 , i.p.) over five weeks prior to behavioral training reversed associative memory deficits in the Tg2576 mouse model of familial AD. This reversal was accompanied by restored dendritic spine density and increased expression of several heat-shock proteins (75) .
Together with the recent finding that the AD-related neurodegenerative brain is characterized by decreased histone acetylation at the promoter regions of important memory-promoting genes (56), mediated in part by HDAC2, these findings strongly advocate for the further development of HDAC2-selective inhibitors. Such inhibitors would restore histone acetylation levels and, in the process, restore cognitive functions to nondiseased levels (Figure 1a) .
HDAC Inhibitors as Cognitive Enhancers
The fact that HDACis can restore memory functions to normal levels in cognitively impaired animals brings up the question, can HDACis also serve as true cognitive enhancers, i.e., can they further improve healthy cognitive capacities (Figure 1a) ? The experimental evidence is mixed. Several of the aforementioned studies included healthy control animals treated with HDACis and showed no further improvement of their memory capacities. Such an absence of cognitive enhancement was noted in wild-type C57Bl/6 animals treated acutely with TSA (2 mg kg −1 , i.p.) for object-recognition memory (40) and in wild-type littermates of APP/PS1 mice treated acutely or chronically with NaB (1.2 g kg −1 , i.p.) for fear memory (50, 74) , and presumably in other studies, which did not report their negative results.
These negative results notwithstanding, several other studies did report cognitive enhancement with HDACis in wild-type animals. Fear-potentiated startle, an indicator of fear associated with a threatening stimulus, was increased in rats treated acutely with TSA (400 nM; stereotaxic injections into the amygdala) 24 h, but not 2 h, after training (76) . Similarly, contextual fear memory was improved in rats treated acutely with NaB (1.2 g kg −1 , i.p.) 24 h, but not 1 h, after training (6). This finding was later recapitulated in mice treated chronically with NaB (1.2 g kg −1 , i.p.) (62, 73), for which the effect was accompanied by increased histone acetylation on H3K14 and H4K5 as well as by increased synaptic density. Interestingly, administering NaB chronically before training or acutely immediately thereafter had the same memory-boosting effect, and giving the HDACi either i.p. or i.c.v. (100 ng NaB or 50 ng TSA) yielded comparable results (73) .
Along these lines, chronic treatment with another HDACi, SAHA (50 mg kg −1 , i.p.), also resulted in enhanced contextual fear memory performance in mice (62). Interestingly, this effect was dose dependent: A 25 mg kg −1 dose had a better outcome on contextual fear memories than a 16.6 mg kg −1 dose when given over 10 days i.p. in a head-to-head comparison. These memory improvements were further accompanied by increased synaptic density and dendritic arborization. Similarly, acute administration of TSA (16.5 mM; stereotaxic injection into the dorsal hippocampus) after contextual fear conditioning significantly enhanced memory retention 24 h later (77) (78) . Following HDACi treatment, these two genes also showed a concomitant increase in expression (77) . Comparable results were obtained when TSA (1 μg μl −1 stereotaxic injection into the basolateral amygdala) was administered after auditory fear conditioning (25) or after reexposure to the cue when it enhanced memory reconsolidation (24) .
Importantly, memory-promoting effects of HDACis are not limited to fear-associated forms of memory. Chronic administration of NaB (1.2 g kg −1 , i.p.), as well as acute or chronic treatment with valproic acid derivatives, improved spatial memories on the water maze task (73, 79, 80) , and acute administration of NaB (0.6 g kg −1 or 1.2 g kg −1 , i.p.) immediately following training enhanced object-recognition memory both 1 day and 7 days after training but not 90 min after training (81) . Posttraining targeted infusions of NaB (both 1 μg and 10 μg) into the hippocampus and insular cortex also enhanced object-location and object-recognition memory, respectively (82). For object-recognition memories, similar results were obtained with posttraining hippocampal infusions of TSA (16.5 mM) or the benzamide-type HDACi MS-275 (1 mM) (83) . Related to this, RGFP136, a HDAC3-selective inhibitor of the benzamide group of HDACis, also facilitated object location memories (63).
Finally, HDACis have also been successfully used as memory enhancers in invertebrates. In Aplysia, TSA administration allowed long-term facilitation in the presence of a weak training protocol (67) , and in the crab Chasmagnathus granulatus, the administration of NaB and TSA allowed a weak training protocol to induce lasting long-term memories (29) .
Taken together, several lines of evidence indicate that HDACis could be considered cognitive enhancers (Figure 1a) . Namely, the fact that similar observations have been made across different species, memory tasks, memory phases, routes of administration, and types of HDACis is encouraging. Moreover, the absence of a memory-improving effect shortly after training (ranging from minutes to hours) and the presence of such an enhancement for long-term memories (ranging from days to weeks) are in line with the following two ideas: (a) that short-term memories are transcription independent (84) and therefore not amenable to interventions at the epigenetic level and (b) that long-term memories are transcription dependent (1, 84) and thus more likely to be modified by epigenetic interventions via HDACis. However, several pitfalls described in the next section still caution against becoming overly enthusiastic when considering HDACis as cognitive enhancers.
FEASIBILITY OF HDAC INHIBITORS AS COGNITIVE ENHANCERS?

Lack of Selectivity
No fully selective inhibitors for any given HDAC have been tested in the brain (61, 70). Thus, it is unclear which HDACs should be targeted for cognitive enhancement. Focally deleting hippocampal HDAC3 enhanced object-location memory (63), so the idea of targeting HDAC3 for cognitive enhancement seemed promising; however, such a deletion failed to enhance performance on other memory tasks, suggesting that the role of HDAC3 might be restricted to object-related memories involving a spatial component. Mice with HDAC2 knocked out in the brain displayed enhanced fear and spatial memories (62), and we recently obtained similar results by virally reducing HDAC2 levels specifically in hippocampal area CA1 ( J. Gräff & L.-H. Tsai, unpublished observations). Thus, HDAC2 seems to be the best target for cognitive enhancement so far. However, because HDAC2 is structurally almost identical to HDAC1 and often found in the same repressor complexes (13) , teasing HDAC1 and HDAC2 apart will constitute a huge chemical challenge. Until this is achieved, caution must be taken when inhibiting HDAC1/2.
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For instance, HDAC1 is neuroprotective in mice, rats, and C. elegans (85, 86) , so it is more desirable for activation than for inhibition. To boot, HDAC2 is required for adult neurogenesis (87) , which, in turn, is implicated in memory formation (88) . Although the HDAC2 genetic knockdown plus the class I-specific inhibitor data so far seem to indicate that the beneficial effects of inhibiting class I HDACs-HDAC2 in particular-might outweigh any such pitfalls, more refined studies, especially long-term ones, are needed to address these concerns.
Another level of lack of selectivity concerns the absence of good biomarkers for treatment with HDACis. Histone acetylation marks are the obvious target, but histone acetylation cannot be considered the mirror image of a given HDAC's activity because HDACs target histones in an unspecific manner (in contrast to, e.g., histone methyltransferases) (89) . As an alternative, candidate memory-enhancing genes, such as the immediate early genes c-fos and zif268 (22, 63) , which are known to be regulated by HDACi treatment, might be envisaged as biomarkers, at least in animals. However, as other signaling cascades might also drive the expression of these memory-enhancing genes, they would at best constitute indirect biomarkers. Additionally, in humans, any potential biomarker ought to be surveyed noninvasively. Although such surveillance is challenging, a recent study directly monitored the presence of the HDACi MS-275 via positron emission tomography in the rodent and nonhuman primate brain following peripheral administration (90) . The finding was somewhat disappointing-MS-275 was shown to have low blood-brain-barrier penetrance-but this study nevertheless demonstrated a proof of principle of the effectiveness of positron emission tomography at providing brain pharmacokinetic data for HDACis.
Side Effects
With respect to translational implications for the use of HDACis as cognitive treatments or enhancers, the route of administration becomes a key issue. Researchers are pursuing systemic methods of administration, but such methods might trigger side effects in nontargeted organs. Two studies reported neurotoxic effects upon HDACi treatment in animal models (91, 92) . Strikingly, because these treatments were administrations of NaB and TSA, the neurotoxic effects might be due to the inhibition of the neuroprotective HDAC1. To our knowledge, no other reports of side effects in animal models exist. Given the extensive use of HDACis as potential cancer treatments, some side effects have also been reported in humans. These are dose-dependent and include thrombocytopenia, fatigue, confusion, hepatotoxicity, and abnormal electrocardiograph effects (70) . In general, however, HDACis are well tolerated (60), which is surprising given that systemic routes of administration preclude tissue or even cell-type specificity.
This absence of drastic side effects in humans and animal models alike is even more surprising given the extensive cross talk of histone acetylation with other epigenetic modifications (93) and the resulting downstream consequences when only one epigenetic mark is affected. Because the brain performs a plethora of functions other than cognition, the notion of epigenetic cross talk is of particular importance in this organ. For instance, mood, anxiety, and depression also involve epigenetic modifications (35) . In addition, chronically depressed patients as well as mice exposed to chronic social-defeat stress (a depression-like behavior-inducing paradigm in rodents) display reduced HDAC2 levels in the nucleus accumbens (94), a brain area involved in reward. Thus, reducing or inhibiting HDAC2 levels might not be desired in all brain areas. It would therefore be important to investigate histone acetylation (and other epigenetic modifications) in brain areas other than the ones involved in cognitive functions upon HDACi treatment aimed at memory enhancement. Doing so would help clarify whether a systemic administration results in systemic effects or only in effects in the targeted tissue. However, to our knowledge, such detailed studies are still lacking.
EE: environmental enrichment
Epigenetic Priming?
How is it possible that when administered systemically, HDACis seem to exert their effects preferentially in brain areas involved in learning and memory? One answer might lie in epigenetic priming, a concept arising from cancer research. For example, administration of a DNAhypomethylating drug (decitabine) significantly improved response rates in leukemic patients subsequently treated with chemotherapy (95), presumably by rendering the epigenome more permissive for the expression of tumor-suppressor genes. Similar results have been obtained by administration of HDACis, which facilitated the reexpression of previously silenced (tumor-suppressor) genes by increasing histone acetylation in cancer cells (96), thereby sensitizing or priming the cells' response to subsequent treatments (59). Because cancer cells are aberrantly dividing at high rates, and thus hyperactive, it follows that HDACis might have a more pronounced effect in cell populations that are by default already characterized by increased activity. The effectiveness of HDACis in increasing histone acetylation is likely to be potentiated when the chromatin is characterized by a permissive structure in the first place.
This epigenetic priming concept is applicable to cognitive processes in the brain as well. Learning per se can trigger histone acetylation changes in the hippocampus (6), rendering the chromatin around certain genes more permissive (23, 31) . Thus, applying HDACis around the time of learning is likely to have a more pronounced effect in this particular brain area, which through learning has already been primed with a more open chromatin structure (Figure 1b) . This neuronal activityinduced chromatin remodeling is likely to be triggered by HDAC2 because HDAC2 dissociates from the chromatin upon stimulation by brain-derived neurotrophic factor (97), which itself is induced through neuronal activity-driven calcium-dependent derepression (98). Importantly, such a concept applies to both the treatment of cognitive disorders and the enhancement of memory because learning, i.e., the exposure to something novel, is likely to activate memory-related brain areas regardless of the overall health status of the brain. Under this epigenetic priming model, HDACi treatment would reinforce already occurring gene expression activity, and its effect in other brain regions or tissues with low baseline activity would be minimal (Figure 1b) , potentially excluding undesired side effects. Interestingly, the epigenetic priming can occur either by the neuronal activity or by the administration of the HDACi, depending on which is applied first: This would also explain why HDACis are effective at enhancing memories when administered both before and after training. However, the concept of cognitive epigenetic priming remains to date theoretical.
NATURAL COGNITIVE ENHANCERS WITH HDACi-LIKE PROPERTIES
Memory-enhancing effects like those caused by HDACis may also be achieved by natural regimens that are beneficial for memory capacities. These include environmental enrichment (EE) and dietary regimens.
Environmental Enrichment
The effect of NaB on reestablishing memory capacities in the CK-p25 mice with profound neuronal loss could be mimicked by providing the animals with a daily-changing enriched environment that consists of running wheels, climbing devices, hidden nutrients, and increased social interaction (73) . EE did not prevent neuronal loss, but it reinstated structural plasticity in the surviving neurons. Strikingly, this reinstated structural plasticity correlated with an increase www.annualreviews.org • Cognitive Enhancement with HDACisin histone acetylation on H3 and H4, similar to the effect of NaB treatment in wild-type mice. In a similar manner, EE also reversed schizophrenia-associated memory impairments via EE-induced hyperacetylation on H3K9 (68) . The effect of EE was mediated by the HAT CBP, as CBP +/− mice failed to show EE-induced improvements in associative and spatial memory tests (99). Thus, EE constitutes an attractive alternative to HDACis to improve cognition.
Dietary Regimens
Calorie restriction (CR), the reduction in the number of daily consumed calories, has long been known to extend life expectancy in a variety of organisms (100), and it also alleviates memory deficits in mouse models of AD (101-103) and improves memory performance in elderly humans (104). One of the best-understood pathways by which CR exerts its effects is via activating the class III HDACs, the sirtuins (105) (see also Related Resources), but recently other HDACs have also shown responsiveness to CR. Following fasting, hypothalamic expression of HDAC3 and HDAC4 increased, whereas the expression of HDAC10 and HDAC11 decreased (106). In future studies, it will be of particular interest to assess the expression profiles of HDACs upon CR in brain areas implicated in learning and memory.
ETHICAL CONSIDERATIONS
Although using cognitive enhancement to treat cognitive decline and thereby to reduce substantial monetary and psychological costs to individuals and families suffering from cognitive inabilities is certainly desirable, applying it to cognitively healthy individuals is a double-edged sword (107-109). As with any other performance-enhancing drug, inequality between users and nonusers is likely to be reinforced. Such potential cognitive enhancement-driven disparity in memory performance might indeed widen the socioeconomic gap between those who can and those who cannot afford this treatment. Moreover, we might start to see a phenomenon known as coercion: As soon as some start to take cognitive enhancers, others will need to follow suit to stay competitive, despite their reluctance to resort to chemical stimulants.
An anonymous online survey by Nature in 2008 revealed that a stunning 20% of its subscribers reported taking memory-enhancing drugs such as methylphenidate (Novartis's Ritalin R ) or amphetamine on a regular basis (110), and this behavior is probably also commonplace among students. Therefore, pharmacological cognitive enhancement has already begun, and society ought to start thinking about policies to regulate it.
CONCLUSIONS
In sum, HDACis have great potential as pharmacological treatments against neurological diseases characterized by memory impairments or as cognitive enhancers in the cognitively healthy. Their broad applicability and the remarkable absence of severe side effects strengthen this point. In contrast to the targeted therapeutic approaches aimed at enhancing cognition (111), HDACis represent a broader treatment at the level of chromatin, making it theoretically accessible to all genes implicated in learning and memory. Although alluring, such a nonspecific approach inherently harbors a greater potential for undesired side effects; therefore, any concerns about safety apply with even more vigor to HDACis. Nonetheless, HDACis might make it possible to reinstate some of brain cells' natural chromatin plasticity that is lost during development or disease via epigenetic modifications, and thus to restore previously constrained or seemingly dormant cognitive potential.
